Invokana Renal Failure Lawsuit Filed Over Side Effects of Diabetes Drug

Only about one year after switching to a new diabetes treatment, a product liability lawsuit indicates that side effects of Invokana resulted in renal failure, requiring hospitalization and substantial medical treatment. 

In a complaint (PDF) filed last week in the U.S. District Court for the District of New Jersey, Merdies V. Burrison indicates that Invokana never would have been used if the drug makers had properly disclosed the kidney risks associated with the diabetes treatment.

Burrison began taking Invokana in May 2014, indicating in the lawsuit that the medication was the direct and proximate cause of a renal failure diagnosis received in June 2015.

“Plaintiff agreed to initiate treatment with Invokana in an effort to reduce her blood sugar. In doing so, Plaintiff relied on claims made by Defendants that Invokana was safe and effective for the treatment of diabetes,” the lawsuit states. “Instead, Invokana can cause severe injuries, including heart attack, stroke, renal failure, renal impairment, renal insufficiency, kidney injury and diabetic ketoacidosis.”

Allegations raised in the complaint are similar to those presented in a growing number of other Invokana lawsuits, which are currently centralized before U.S. District Judge Brian R. Martinotti in New Jersey, as part of a federal MDL, or multidistrict litigation.

Given similar questions of fact and law raised in the Invokana litigation, Judge Martinotti is coordinating pretrial proceedings to reduce duplicative discovery into common issues, avoid conflicting pretrial rulings and to serve the convenience of the parties, witnesses and the judicial system.

Invokana Litigation

Invokana (canagliflozin) was introduced in March 2013, as the first member of a new class of diabetes drugs, known as sodium-glucose cotransporter 2 (SGLT2) inhibitors, which works in a unique way by impacting some normal kidney functions. Other members of this class include Invokamet, Jardiance, Farxiga, Xigduo and others, but Invokana has remained the biggest seller, amid aggressive marketing.

As more and more diabetics have switched to Invokana, a steady stream of serious health concerns have emerged from post-marketing adverse event reports, leading the FDA to require several warning label updates over the past few years.

In December 2015, the FDA required Johnson & Johnson to add new diabetic ketoacidosis warnings to Invokana, indicating that the medication increases the risk of this serious condition, which typically results in the need for emergency treatment to avoid life-threatening injury. Prior to the update, the Invokana warnings failed to alert consumers about the importance of seeking immediate medical attention if they experience symptoms like abdominal pain, fatigue, nausea, respiratory problems or vomiting.

In June 2016, the FDA required additional label warnings about the link between  Invokana and kidney risks, indicating that the medication may increase the risk of acute kidney injury and other severe health problems.

More recently, in May 2017, the FDA required an Invokana warning update regarding the risk of leg and foot amputation, which manufacturers of other SGLT2 inhibitors claim is a unique risk with Invokana, not seen with their competing drugs.

As part of the coordinated pretrial proceedings in the federal court system, it is expected that a small group of “bellwether” cases will be prepared for early trial dates to help the parties gauge how juries may respond to certain evidence and testimony that will be repeated throughout the litigation.

Following any bellwether trials, if Invokana settlements or another resolution for the cases is not found, Burrison’s’ claim and hundreds of others may later be remanded to U.S. District Courts nationwide for separate trial dates.